Drug-Induced Liver Injury [see Warnings and Precautions (5.10)] Grade 3 ALT or higher in the absence of another cause4 OR AST/ALT greater than 3 × upper limit normal (ULN) with bilirubin greater than 2 × ULN in the absence of another cause4 Permanently discontinue. Non-hematological to...
UsesSorafenib, an orally active potent multi-kinases inhibitor,was approved in the U.S. for the treatment of advanced renalcell carcinoma. The drug targets both tumor cell proliferationand tumor angiogenesis kinases that include RAF,VEGFR-2, VEGFR-3, PDGFR-b, KIT and FLT-3. Sorafenibis being...
Cardiotoxicity is an emerging concern with a new class of drugs known as targeted agents, which include trastuzumab and sunitinib. Sunitinib is a small molecule that inhibits multiple tyrosine kinase receptors. This drug was approved by the United States Food and Drug Administration in 2006 for the...
However, grade 3 drug-related AEs were more common in the sorafenib group and included diarrhea (8%), hand–foot skin reaction (HFSR) (8%), hypertension (2%) and abdominal pain (2%). The rate of patients who discontinued treatment was similar in the two groups (38 and 37%, ...
In addition, recent studies have demonstrated that cytoskeletal proteins may be associated with drug resistance in HCC [13, 14]. However, the mechanism of sorafenib resistance in HCC still needs further study. Tumor resistance is closely related to single-stranded DNA (ssDNA) [15,16,17,18]. ...
The small drug Sorafenib (Nexavar, Bayer HealthCare Pharmaceuticals) enhances the rate of apoptosis while inhibiting tumor cell growth and tumor angiogenesis [8]. Sorafenib is considered the sole systemic medicine that enhances overall survival in patients with advanced-stage HCC. Compared to a placebo...
is a first-line targeted drug approved by the US Food and Drug Administration for advanced HCC [2]. According to the results of the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial, sorafenib can prolong survival of HCC patients. However, drug resistance limits its ef...
There were four severe gastrointestinal bleedings (grade 4-5; Child-Pugh class B/C, 2/2). Most drug-related side effects were low grade and manageable irrespective of liver function. Sorafenib is effective and safe in patients with multifocal HCC and Child-Pugh class A cirrhosis. Survival in...
In a 77-year-old, I would have started at either 4 mg or 8 mg, depending on how biologically fit she looked and also how tolerant of AEs I thought she would be. Some people have AEs, and that is thatthey will never take the drug again. Other people will say, “I&rsquo...
These data demonstrate that NUPR1 may have an oncogenic potential in HCC and it may be involved in drug resistance. This was further confirmed after generation of NUPR1 knockdown stable clones using NUPR1-specific short hairpin RNA (shRNA), in which NUPR1 gene silencing significantly decreased ...